NANOVIRICIDES, Inc. (NNVC) intrinsic value & 10-year financials
NANOVIRICIDES, Inc. (NNVC) has no Graham intrinsic value right now because the formula needs positive earnings. Over the last 10 fiscal years revenue reached to $0, with an average return on invested capital of -85.6%.
- Graham intrinsic value
- —
- Share price (Oct 17, 2026)
- $1.38
- Market cap
- $20.9M
- Revenue (FY2025)
- $0
- ROIC (10-yr avg)
- -85.6%
- Free cash flow (FY2025)
- -$8.5M
NNVC 10-year financial history
| Fiscal year | Revenue | Net income | EPS (diluted) | Free cash flow | Operating margin | ROIC |
|---|---|---|---|---|---|---|
| FY2025 | $0 | -$9.5M | -$0.63 | -$8.5M | — | -99.7% |
| FY2024 | $0 | -$8.3M | -$0.70 | -$6.5M | — | -63.0% |
| FY2023 | $0 | -$8.6M | -$0.74 | -$5.8M | — | -45.3% |
| FY2022 | — | -$8.1M | -$0.70 | -$6.2M | — | -30.6% |
| FY2021 | — | -$8.8M | -$0.81 | -$8.5M | — | -34.1% |
| FY2020 | — | -$13.4M | — | -$6.7M | — | -49.4% |
| FY2019 | — | -$8.4M | — | -$6.9M | — | -61.3% |
| FY2018 | — | -$8.6M | -$0.13 | -$8.0M | — | -49.1% |
| FY2017 | — | -$10.3M | -$0.17 | -$8.1M | — | -220.2% |
| FY2016 | — | -$10.7M | -$0.19 | -$7.3M | — | -203.2% |
Source: annual 10-K filings on SEC EDGAR. Figures in USD.
Executive summary
NANOVIRICIDES, INC. revenue growth over the past decade is N/A; insufficient history prevents a reliable 10-year CAGR calculation.
NANOVIRICIDES, INC. has historically struggled to out-earn its cost of capital, averaging just -43.7% ROIC.
Over the decade, NANOVIRICIDES, INC. shows that management has aggressively returned capital to shareholders by retiring 73.8% of outstanding shares.
Benjamin Graham lens
NANOVIRICIDES, INC. is evaluated under Benjamin Graham's defensive framework using SEC EDGAR fundamentals using an 8.5 + 2g earnings multiple and a 5.1% AAA bond-yield baseline.